PURPOSE: Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHH tumors. PATIENTS AND METHODS: We combined transcriptome and DNA copy-number analyses for 64 primary medulloblastomas. Bioinformatic tools were used to discover marker genes of molecular variants. Differentially expressed transcripts were evaluated for prognostic value in the screening cohort. The prognostic power of follistatin-like 5 (FSTL5) immunopositivity was tested for 235 nonoverlapping medulloblastoma samples on two independent tissue microarrays. RESULTS: Comprehensive analyses of transcriptomic and genetic alterations delineate four distinct variants of medulloblastoma. Stable subgroup separation was achieved by using the 300 transcripts that varied the most. Distinct expression patterns of FSTL5 in each molecular subgroup were confirmed by quantitative real-time polymerase chain reaction. Immunopositivity of FSTL5 identified a large cohort of patients (84 of 235 patients; 36%) at high risk for relapse and death. Importantly, more than 50% of non-WNT/non-SHH tumors displayed FSTL5 negativity, delineating a large patient cohort with a good prognosis who would otherwise be considered intermediate or high-risk on the basis of current molecular subgrouping. CONCLUSION: FSTL5 expression denoted a dismal prognosis both within and across medulloblastoma subgroups. The addition of FSTL5 immunohistochemistry to existing molecular stratification schemes constitutes a reliable and cost-effective tool for prognostication in future clinical trials of medulloblastoma.
PURPOSE: Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHHtumors. PATIENTS AND METHODS: We combined transcriptome and DNA copy-number analyses for 64 primary medulloblastomas. Bioinformatic tools were used to discover marker genes of molecular variants. Differentially expressed transcripts were evaluated for prognostic value in the screening cohort. The prognostic power of follistatin-like 5 (FSTL5) immunopositivity was tested for 235 nonoverlapping medulloblastoma samples on two independent tissue microarrays. RESULTS: Comprehensive analyses of transcriptomic and genetic alterations delineate four distinct variants of medulloblastoma. Stable subgroup separation was achieved by using the 300 transcripts that varied the most. Distinct expression patterns of FSTL5 in each molecular subgroup were confirmed by quantitative real-time polymerase chain reaction. Immunopositivity of FSTL5 identified a large cohort of patients (84 of 235 patients; 36%) at high risk for relapse and death. Importantly, more than 50% of non-WNT/non-SHHtumors displayed FSTL5 negativity, delineating a large patient cohort with a good prognosis who would otherwise be considered intermediate or high-risk on the basis of current molecular subgrouping. CONCLUSION:FSTL5 expression denoted a dismal prognosis both within and across medulloblastoma subgroups. The addition of FSTL5 immunohistochemistry to existing molecular stratification schemes constitutes a reliable and cost-effective tool for prognostication in future clinical trials of medulloblastoma.
Authors: Shyamal Dilhan Weeraratne; Vladimir Amani; Natalia Teider; Jessica Pierre-Francois; Dominic Winter; Min Jeong Kye; Soma Sengupta; Tenley Archer; Marc Remke; Alfa H C Bai; Peter Warren; Stefan M Pfister; Judith A J Steen; Scott L Pomeroy; Yoon-Jae Cho Journal: Acta Neuropathol Date: 2012-03-10 Impact factor: 17.088
Authors: Cemile G Guldal; Adiba Ahmad; Andrey Korshunov; Massimo Squatrito; Aashir Awan; Lori A Mainwaring; Bipin Bhatia; Susana R Parathath; Zaher Nahle; Stefan Pfister; Anna M Kenney Journal: Acta Neuropathol Date: 2012-04 Impact factor: 17.088
Authors: André O von Bueren; Joachim Gerss; Christian Hagel; Haoyang Cai; Marc Remke; Martin Hasselblatt; Burt G Feuerstein; Sarah Pernet; Olivier Delattre; Andrey Korshunov; Stefan Rutkowski; Stefan M Pfister; Michael Baudis Journal: J Neurooncol Date: 2012-07-07 Impact factor: 4.130
Authors: Thora Gudrunardottir; Birgitta Lannering; Marc Remke; Michael D Taylor; Elizabeth M Wells; Robert F Keating; Roger J Packer Journal: Childs Nerv Syst Date: 2014-02-26 Impact factor: 1.475
Authors: Jing Dong; Annah Wyss; Jingyun Yang; T Ryan Price; Aude Nicolas; Michael Nalls; Greg Tranah; Nora Franceschini; Zongli Xu; Claudia Schulte; Alvaro Alonso; Steven R Cummings; Myriam Fornage; Dmitri Zaykin; Leping Li; Xuemei Huang; Stephen Kritchevsky; Yongmei Liu; Thomas Gasser; Robert S Wilson; Philip L De Jager; Andrew B Singleton; Jayant M Pinto; Tamara Harris; Thomas H Mosley; David A Bennett; Stephanie London; Lei Yu; Honglei Chen Journal: Mol Neurobiol Date: 2016-11-23 Impact factor: 5.590
Authors: Ina Oehme; Jan-Peter Linke; Barbara C Böck; Till Milde; Marco Lodrini; Bettina Hartenstein; Inga Wiegand; Christian Eckert; Wilfried Roth; Marcel Kool; Sylvia Kaden; Hermann-Josef Gröne; Johannes H Schulte; Sven Lindner; Anne Hamacher-Brady; Nathan R Brady; Hedwig E Deubzer; Olaf Witt Journal: Proc Natl Acad Sci U S A Date: 2013-06-25 Impact factor: 11.205